Full history for every metric is available with a Kvantra account
Ekso Bionics Holdings, Inc. (EKSO)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 9 | 11 | 13 | 18 | 18 | 13 | 12 |
| Operating profit | $m | -13 | -16 | |||||
| Net profit | $m | -16 | -10 | -15 | -15 | -11 | -12 | -16 |
| EPS reported | $ | -4.91 | -5.39 | |||||
| Operating cashflow per share | $ | -4.86 | -3.36 | |||||
| Capex per share | $ | 0.08 | 0.01 | |||||
| FCF per share | $ | -4.94 | -3.37 | |||||
| Free cash flow | $m | -12 | -12 | |||||
| Net debt | $m | 3 | -0 | |||||
| Book value equity | $m | 9 | 6 | |||||
| Book value per share | $ | 3.72 | 1.61 | |||||
| Number of shares | m | 2.43 | 3.56 | |||||
| DPS (TTM paid) | $ | 0.09 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.32 | 6.72 | |||||
| P/S LTM | x | 1.64 | 3.34 | |||||
| P/FCF LTM | x | -1.75 | -3.21 | |||||
| EV/EBITDA LTM | x | -2.49 | -2.89 | |||||
| EV/Sales LTM | x | 1.91 | 3.33 | |||||
| Earnings Yield LTM | % | -55.80% | -27.69% | |||||
| FCF Yield | % | -57.20% | -31.11% | |||||
| Quality | ||||||||
| ROE | % | -129.56% | -177.40% | |||||
| ROIC | % | -87.82% | -108.78% | |||||
| Operating margin | % | -104.12% | -134.06% | |||||
| Gross margin | % | 53.48% | 52.86% | |||||
| FCF/Sales | % | -93.67% | -103.75% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -28.60% | -34.08% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 1.08% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -1.90% | 0.00% | |||||
| FCF/Debt | x | -2.58 | -2.78 | |||||
| Net Debt/EBITDA | x | -0.35 | -0.02 | |||||
| EBIT/Net interest | x | -43.13 | -22.47 | |||||
| Net debt/market cap | % | 13.77% | -0.07% | |||||
| Net debt/Equity | x | 0.32 | -0.00 | |||||
| Gross debt/equity | x | 0.51 | 0.75 | |||||
Company overview
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It also develops Ekso Nomad, a power Knee Ankle Foot Orthosis or KAFO; and MediTouch BalanceTutor rehabilitation system, a multidirectional perturbation treadmill outfitted. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ekso Bionics Holdings, Inc. (EKSO)
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It also develops Ekso Nomad, a power Knee Ankle Foot Orthosis or KAFO; and MediTouch BalanceTutor rehabilitation system, a multidirectional perturbation treadmill outfitted. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free